Moderna Receives FDA Fast Track Designation for Propionic Acidemia Program (mRNA-3927)
mRNA-3927 is Moderna’s second rare disease program to receive Fast Track designation
mRNA-3927 uses the same proprietary LNP formulation as mRNA-1944 (antibody against Chikungunya virus) and mRNA-3704 (methylmalonic acidemia)
“Propioic acidemia is caused by the inability of the body to breakdown certain proteins and fats which leads to the build-up of toxic chemicals. The disease is characterized by life-threatening illnesses in response to minor stressors, neurological dysfunction and cardiomyopathy,” said
“Fast Track designation underscores the urgent need for a therapy that treats the underlying cause of propionic acidemia,” said
Fast Track is designed to facilitate the development and expedite the review of therapies and vaccines for serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from early and frequent communication with the
PA and MMA are rare diseases that share similar disease pathology and are both typically treated by metabolic specialists. In order to characterize and describe the natural history of these disorders and identify potential clinical and biomarker endpoints,
mRNA-3927 is designed to instruct the body to restore the missing or dysfunctional proteins that cause PA. mRNA-3927 contains two mRNAs that encode for the alpha and beta subunits of the mitochondrial enzyme propionyl-CoA carboxylase (PCC), encapsulated within Moderna’s proprietary lipid nanoparticle (LNP). mRNA-3927 is intended to treat patients with PA regardless of whether they are missing the alpha or beta subunits. mRNA-3927 uses the same proprietary LNP formulation used in the Company’s antibody against chikungunya virus (mRNA-1944) and MMA (mRNA-3704) programs.
In addition to Fast Track designation, mRNA-3927 has also been granted Orphan Drug and Rare Pediatric Disease designations from the
About Propionic Acidemia (PA)
PA is a rare, life-threatening, inherited metabolic disorder that is the result of a deficiency in PCC that is an enzyme critical for metabolism. This deficiency can lead to a toxic buildup of acids in the body. Symptoms of PA typically become apparent during infancy and may include weak muscle tone, poor feeding, vomiting and lack of energy. More severe health problems can also occur, including heart abnormalities, seizures and coma.
The only effective treatment for severely affected individuals is liver transplant, which replaces the deficient PCC enzyme. Currently there are no approved therapies to treat the underlying cause of PA, including no enzyme replacement therapy, due to the complexity of the PCC enzyme that requires mitochondrial localization.
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended including, but not limited to, statements concerning: Moderna’s plans to initiate an open-label, multi-center, dose escalation Phase 1/2 study of multiple ascending doses of mRNA-3927; mRNA-3927’s potential to restore enzyme activity in children with PA; and mRNA-3927’s potential for patients with PA regardless of whether they have defects in the alpha or beta subunits of PCC. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others: whether the Phase 1 results for mRNA-1944 will be predictive of any future clinical studies for other development candidates with the same lipid nanoparticle (LNP) formulation, including mRNA-3927 and mRNA-3704; the fact that clinical development is lengthy and uncertain, especially for a new class of medicines such as mRNA, and therefore Moderna’s clinical programs or development candidates may be delayed, terminated, or may never advance; no mRNA drug has been approved in this new potential class of medicines, and may never be approved; mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new class of medicines; and those risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Annual Report on Form 10-K filed with the
Senior Manager, Corporate Communications
Head of Investor Relations